Mervin C Yoder

US Patent:

20010051611, Dec 13, 2001

Filed:

Jul 24, 2001

Appl. No.:

09/912680

Inventors:

Arun Srivastava - Indianapolis IN, US
Selvarangan Ponnazhagan - Cleveland OH, US
Robert Schloemer - Indianapolis IN, US
Xu-Shan Wang - Carmel IN, US
Mervin Yoder - Indianapolis IN, US
Jaime Escobedo - Alamo CA, US
Varavani Dwarki - Alameda CA, US

Assignee:

Chiron Corporation.

International Classification:

A61K048/00
C12N015/861

US Classification:

514/044000, 435/320100

Abstract:

Provided are methods for selectively expressing therapeutic molecules, such as secretory proteins, antisense molecules and ribozymes, in the liver. The methods find use in treating hepatic diseases or conditions. The methods also find use in treating any disease or condition in which systemic administration of the therapeutic substance, for example, a secretory protein, is desired. The methods involve administering to a mammalian patient having a need for liver expression of a therapeutic molecule an AAV vector containing a therapeutically effective amount of the therapeutic molecule. Also provided are novel vectors employable in these methods.

US Patent:

20030166284, Sep 4, 2003

Filed:

Mar 28, 2002

Appl. No.:

10/109799

Inventors:

Arun Srivastava - Indianapolis IN, US
Selvarangan Ponnazhagan - Cleveland OH, US
Robert Schloemer - Indianapolis IN, US
Xu-Shan Wang - Carmel IN, US
Mervin Yoder - Indianapolis IN, US
Jaime Escobedo - Alamo CA, US
Varavani Dwarki - Alameda CA, US

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

A61K048/00
C12N015/861

US Classification:

435/456000, 424/093200

Abstract:

Provided are methods for selectively expressing therapeutic molecules, such as secretory proteins, antisense molecules and ribozymes, in the liver. The methods find use in treating hepatic diseases or conditions. The methods also find use in treating any disease or condition in which systemic administration of the therapeutic substance, for example, a secretory protein, is desired. The methods involve administering to a mammalian patient having a need for liver expression of a therapeutic molecule an AAV vector containing a therapeutically effective amount of the therapeutic molecule. Also provided are novel vectors employable in these methods.

US Patent:

20050266556, Dec 1, 2005

Filed:

Feb 9, 2005

Appl. No.:

11/055182

Inventors:

Mervin Yoder - Indianapolis IN, US
David Ingram - Indianapolis IN, US

International Classification:

C12N005/08

US Classification:

435372000

Abstract:

A hierarchy of endothelial colony forming cells (EPCs) was identified from mammalian cord blood, umbilical vein and aorta. A newly isolated cell named high proliferative potential—endothelial colony forming cell (HPP-ECFC) was isolated and characterized. Single cell assays were developed that test the proliferative and clonogenic potential of endothelial cells derived from cord blood, or from HUVECs and HAECs. EPCs were found to reside in vessel walls. Use of a feeder layer of cells derived from high proliferative potential-endothelial colony forming cells (HPP-ECPCS) from human umbilical cord blood, stimulates growth and survival of repopulating hematopoietic stem and progenitor cells. Stimulation of growth and survival was determined by increased numbers of progenitor cells in in vitro cultures and increased levels of human cell engraftment in the NOD/SCID immunodeficient mouse transplant system.

US Patent:

20080025956, Jan 31, 2008

Filed:

Aug 13, 2007

Appl. No.:

11/837999

Inventors:

Mervin Yoder - Indianapolis IN, US
David Ingram - Indianapolis IN, US
Daniel Prater - Fishers IN, US

Assignee:

Indiana University Research and Technology Corporation - Indianapolis IN

International Classification:

A61K 35/12
A61P 9/00
C12N 5/02
C12N 5/08

US Classification:

424093700, 435325000, 435402000

Abstract:

Methods and compositions to form fully functional blood vessels in vivo using endothelial colony forming cells (ECFCs) are disclosed. Culturing ECFCs in a support material results in association of ECFCs in vitro and formation of blood vessels in vivo upon implantation. Direct administration of cultured ECFCs form blood vessels in vivo. Formation of blood vessels is useful in treating a variety of medical conditions including ischemia and hypoxia.

US Patent:

20090280180, Nov 12, 2009

Filed:

Dec 10, 2008

Appl. No.:

12/332084

Inventors:

Seth Kreger - New Richmond IN, US
Mervin C. Yoder - Indianapolis IN, US
Paul Critser - Indianapolis IN, US

International Classification:

A61K 9/00
A61K 35/12
C12N 5/06
C12N 9/48

US Classification:

424484, 424 937, 435395, 435212

Abstract:

Collagen based-matrices and methods of their use are described. More particularly, collagen-based matrices for differentiating stem cells and progenitor cells, and for producing and isolating blood vessels and vascularized graft constructs are described.

US Patent:

6521225, Feb 18, 2003

Filed:

Sep 2, 1997

Appl. No.:

08/921497

Inventors:

Arun Srivastava - Indianapolis IN
Selvarangan Ponnazhagan - Cleveland OH
Xu-Shan Wang - Carmel IN
Mervin C. Yoder - Indianapolis IN
Jaime Escobedo - Alamo CA
Varavani Dwarki - Alameda CA

Assignee:

Chiron Corporation - Emeryville CA
Advanced Research and Technology Institute - Bloomington IN

International Classification:

A61K 3500

US Classification:

424 932, 424 931

Abstract:

The present invention is directed to a recombinant adenovirus vector comprising two inverted terminal repeats (ITRs) each of which comprises a D-sequence having (i) from 5 to 15 native nucleotides and (ii) one or more deletions or substitutions therein.

US Patent:

20200281986, Sep 10, 2020

Filed:

Sep 6, 2019

Appl. No.:

16/562958

Inventors:

- Indianapolis IN, US
Mervin C. Yoder - Indianapolis IN, US

Assignee:

VASCUGEN, INC. - Indianapolis IN

International Classification:

A61K 35/36
C12N 5/071
C12N 15/85
A61P 17/02

Abstract:

The present disclosure describes the engineering of a mesodermal precursor cell population obtained through the differentiation of induced pluripotent stem cells (iPSCs) for the cell therapy treatment of perfusion disorders. The modifications improve the survival and clonal proliferation of the mesodermal precursor cell population ex vivo and facilitate their migration to sites of ischemic injury in vivo.

US Patent:

20200095557, Mar 26, 2020

Filed:

Sep 24, 2019

Appl. No.:

16/580954

Inventors:

- Indianapolis IN, US
Mervin C. Yoder - Indianapolis IN, US
Nutan Prasain - Boston MA, US

Assignee:

Indiana University Research and Technology Corporation - Indianapolis IN

International Classification:

C12N 5/071
C12N 5/00
C12N 5/077

Abstract:

Co-culture of isolated human induced pluripotent stem cell (iPSC)-derived endothelial and smooth-muscle progenitor cells results in the formation of cellular spheroids having capillary-like structures (referred to herein as ‘capillary fragments’) at their core. Bioprinting of these spheroids into scaffold-free tissue constructs facilitates the development of microvasculature within the engineered tissue. Methods of using these bioprinted engineered tissues for cell therapy are also disclosed.